RxDoctor Payments Data

Tana Vogele, APRN

Family · Oologah, OKNPI 1134478068

Payments from drug & device makers

$438in general payments, 2019–2025

Across 28 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$146
  • AstraZeneca$75
  • Merck$40
  • Pfizer$24
  • Johnson & Johnson$20
  • Abbott$19
  • plus $114 from 7 others

What the payments were for

  • Food & beverage$438100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$438 in reported general payments places this provider in the 50th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$35,094
Medicare patients
147
Services billed
540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban101$73,197
OzempicSemaglutide61$67,897
MounjaroTirzepatide61$65,041
TrulicityDulaglutide28$27,066
XareltoRivaroxaban38$23,722
VraylarCariprazine Hcl11$16,032
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$11,890
JardianceEmpagliflozin13$8,840
BrilintaTicagrelor16$8,552
LinzessLinaclotide14$7,438
BelsomraSuvorexant11$4,920
SymbicortBudesonide/Formoterol Fumarate19$4,501
Omeprazole175$3,654
Celecoxib31$2,654
SynthroidLevothyroxine Sodium27$1,936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$14$92,10789 claims
PfizerEliquis$24$73,197101 claims
Novo NordiskOzempic$146$67,89761 claims
AbbVieVraylar, Linzess, Synthroid$15$25,40652 claims
Johnson & JohnsonXarelto$20$23,72238 claims
AstraZenecaBrilinta, Symbicort$75$13,05335 claims
Boehringer IngelheimJardiance$16$8,84013 claims
MerckBelsomra$40$4,92011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,026 family providers in Oklahoma.

Other family in Oologah

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →